fda compounding semaglutide crackdown 2025 news on off-brand Ozempic products set to take effect, threatening supply and access for many US FDA sends 25 letters

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al

Retatrutide is an investigational triple agonist peptide designed to activate GLP-1, GIP and glucagon receptors

Lifescan Diabetes Institute website

Manage GI side effects aggressively Do not simply power through severe nausea, vomiting, and diarrhea

they represent distinct evolutionary steps in incretin biology

A 66/100 reflects a pattern of issues: pricing thats partially transparent but partially hidden, media logos with no links, pop-up pressure tactics, a cancellation process that left me uncertain, and zero disclaimers for medications not fully supported by science